Charles E. Cooley

Array ( [id] => 19397135 [patent_doc_number] => 12071483 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-08-27 [patent_title] => Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof [patent_app_type] => utility [patent_app_number] => 16/770728 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 54 [patent_no_of_words] => 44160 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16770728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613698 [patent_doc_number] => 20210032351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => EGFRVIII ANTIBODY AND CONJUGATE, AND PREPARATION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/772687 [patent_app_country] => US [patent_app_date] => 2018-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17968265 [patent_doc_number] => 11485779 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-01 [patent_title] => Anti-BMP10 monoclonal antibody or fragment thereof [patent_app_type] => utility [patent_app_number] => 16/771828 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 28 [patent_no_of_words] => 40982 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14130215 [patent_doc_number] => 20190099497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => PEGYLATED GROWTH HORMONE ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/216230 [patent_app_country] => US [patent_app_date] => 2018-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7184 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16216230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16970493 [patent_doc_number] => 11066454 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-20 [patent_title] => Compositions comprising variants and fusions of FGF19 polypeptides [patent_app_type] => utility [patent_app_number] => 16/216402 [patent_app_country] => US [patent_app_date] => 2018-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 39 [patent_no_of_words] => 31212 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16216402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102363 [patent_doc_number] => 20190092857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => METHOD OF MODULATING THE ACTIVITY OF ADRENOMEDULLIN IN A SUBJECT IN NEED OF THERAPEUTIC INTERVENTION FOR ORGAN DYSFUNCTION OR ORGAN FAILURE ASSOCIATED WITH ADRENOMEDULLIN (ADM) ACTIVITY BY ADMINISTERING AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM FRAGMENT TO THE SUBJECT [patent_app_type] => utility [patent_app_number] => 16/214963 [patent_app_country] => US [patent_app_date] => 2018-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16214963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18302060 [patent_doc_number] => 11623951 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Antibodies to R-spondin 3 [patent_app_type] => utility [patent_app_number] => 16/770888 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 10837 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16770888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900805 [patent_doc_number] => 20210179721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => METHOD OF TREATING OR PREVENTING ISCHEMIA-REPERFUSION INJURY [patent_app_type] => utility [patent_app_number] => 16/768159 [patent_app_country] => US [patent_app_date] => 2018-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28347 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16768159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18444536 [patent_doc_number] => 11680094 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Methods for the prevention and treatment of enthesopathy and related disorders [patent_app_type] => utility [patent_app_number] => 16/763597 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 63 [patent_no_of_words] => 13866 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512975 [patent_doc_number] => 20200392233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => ALK7 BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/757959 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 112300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17831457 [patent_doc_number] => 20220268761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => THERAPY MONITORING UNDER TREATMENT WITH AN ANTI-ADRENOMEDULLIN (ADM) BINDER [patent_app_type] => utility [patent_app_number] => 16/756903 [patent_app_country] => US [patent_app_date] => 2018-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14778005 [patent_doc_number] => 20190263900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/158642 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16158642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187552 [patent_doc_number] => 11578121 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Anti-EGF like domain multiple 6 (EGFL6) antibodies [patent_app_type] => utility [patent_app_number] => 16/652929 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9591 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16652929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328381 [patent_doc_number] => 20200299347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => FUSION PROTEIN COMPRISING AN FGF-18 MOIETY [patent_app_type] => utility [patent_app_number] => 16/648677 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793375 [patent_doc_number] => 20190010226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR PREVENTION OR REDUCTION OF ORGAN DYSFUNCTION OR ORGAN FAILURE IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE OR ACUTE CONDITION [patent_app_type] => utility [patent_app_number] => 16/136892 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16136892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793333 [patent_doc_number] => 20190010205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => SERUM ALBUMIN-20K GROWTH HORMONE FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 16/131745 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16131745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16270179 [patent_doc_number] => 20200271666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => PROADRENOMEDULLIN AS INDICATOR FOR RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS [patent_app_type] => utility [patent_app_number] => 16/646495 [patent_app_country] => US [patent_app_date] => 2018-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17118765 [patent_doc_number] => 11129874 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Nucleic acids encoding FGF21-Fc fusion proteins [patent_app_type] => utility [patent_app_number] => 16/117960 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 16 [patent_no_of_words] => 23791 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16117960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022328 [patent_doc_number] => 20210246199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => MULTIPLE SPECIFICITY BINDERS OF CXC CHEMOKINES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/638992 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14158775 [patent_doc_number] => 20190106490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => BINDING PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/103613 [patent_app_country] => US [patent_app_date] => 2018-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16103613 [rel_patent_id] =>[rel_patent_doc_number] =>)